search
Back to results

Study Investigating Whether Robot-assisted Surgery Can Reduce Surgical Complications Following Kidney Transplantation (ORAKTx)

Primary Purpose

End Stage Renal Disease, Kidney Transplant; Complications

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Robot-Assisted Kidney Transplantation
Open Kidney Transplantation
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for End Stage Renal Disease focused on measuring Kidney Transplantation, Robotic Surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adult recipients for renal transplantation Both patients in dialysis as well as pre-emptive For recipients of kidney grafts from deceased donors, inclusion depends on the availabilty of the robotic platform and dedicated surgical team Exclusion Criteria: High degree of calcification of the iliac vessels on the level of external iliac artery defined as occurrence of longitudinal plaques on non-contrast CT-scan in recipient prior to transplantation Highly complex vascular anatomy in the donor kidney requiring multiple anastomoses as evaluated by surgeon Previous kidney transplantation with later allograft nephrectomy as evaluated by the surgeon preoperatively Patients whose abdominal anatomy may prohibit access to and placement of graft in the iliac fossa as evaluated by the surgeon preoperatively (i.e. previous laparotomy, rectal surgery, herniotomy, current multiple kidney cysts) Simultaneous multiple organ transplant Severe comorbidities contraindicating robot-assisted surgery Patients who are unable to understand relevant medical information and the implications of treatment alternatives and to make an independent, voluntary decision

Sites / Locations

  • Urological Research Unit, RigshospitaletRecruiting
  • Department of Nephrology, Rigshospitalet

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Robot-assisted Kidney Transplantation (RAKT)

Open Kidney Transplantation (OKT)

Arm Description

Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels. Participants will be managed according to the standard protocol for renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality. The anaestethic protocol will be tailored to suit robot-assisted surgery

Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels. Participants will be managed according to the standard protocol for anaesthesia and renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality.

Outcomes

Primary Outcome Measures

Vascular complications
Composite outcome consisting of a) bleeding requiring reoperation, b) renal/graft vascular thrombosis, c) symptomatic hematomas d) renal/graft arterial stenosis
Surgical complications Clavien-Dindo >grade 2
All postoperative complications will be recorded and graded according to the Clavien-Dindo classification with major complications defined as >grade 2.

Secondary Outcome Measures

Length of Stay (LOS)
Duration (days) of primary hospitalization. From the date of admission until the date of discharge from hospital
Days Alive and Out of Hospital (DAOH)
Number of days alive and out of hospital within 30 days from surgery
Days Alive and Out of Hospital (DAOH)
Number of days alive and out of hospital within 90 days from surgery
Quality of Life (QOL): SF-36
Patient reported health related QOL using the Short Form 36-item Health Survey
Quality of Life (QOL): SF-36
Patient reported health related QOL using the Short Form 36-item Health Survey
Use of analgesics
Average administered dose of any opiod agent (MME/day) post surgery, during in-hospital stay
Transfusion rate
Total amount of red blood cells administered (units)
Kidney Function
30-day creatinine and estimated Glomerular Filtration Rate (eGFR). Creatinine: μmol/L. eGFR calculated according to the CKD-EPI equation
Kidney Function
90-day creatinine and estimated Glomerular Filtration Rate (eGFR). Creatinine: μmol/L. eGFR calculated according to the CKD-EPI equation
Kidney Function
1-year creatinine and estimated Glomerular Filtration Rate (eGFR). Creatinine: μmol/L. eGFR calculated according to the CKD-EPI equation
Kidney Function
2-year creatinine and estimated Glomerular Filtration Rate (eGFR). Creatinine: μmol/L. eGFR calculated according to the CKD-EPI equation
Delayed Graft Function (DGF)
Need for dialysis in the first post-operative week beyond day 0, due to lack of increase in kidney function and where the cause is not urological/surgical complications or hyperkalaemia alone
Graft loss
Start of permanent dialysis and/or allograft nephrectomy
Graft loss
Start of permanent dialysis and/or allograft nephrectomy
Graft loss
Start of permanent dialysis and/or allograft nephrectomy
30-day Mortality
30-day all cause mortality rate and cause of death
90-day Mortality
90-day mortality rate and cause of death
1-year Mortality
1-year mortality rate and cause of death
2-year Mortality
2-year mortality rate and cause of death
Specific urological surgical complications
Ureteral strictures, urinary leak, hydronephrosis, symptomatic lymphocele; including, when needed, designated intervention (nephrostomy, JJ stent, reimplantation, drain, surgery)
Late & specific urological surgical complications
Ureteral strictures, urinary leak, hydronephrosis, symptomatic lymphocele; including, when needed, designated intervention (nephrostomy, JJ stent, reimplantation, drain, surgery)
Late & specific urological surgical complications
Ureteral strictures, urinary leak, hydronephrosis, symptomatic lymphocele; including, when needed, designated intervention (nephrostomy, JJ stent, reimplantation, drain, surgery)
Time to return to work
Whether participants have resumed a paying job 90 days after surgery. If yes: time in months from operation until any degree of work is resumed
Recurrent urinary tract infection (UTI)
Culture confirmed recurrent UTI as defined by EAU guidelines (3 per year or 2 within 6 months)
Recurrent urinary tract infection (UTI)
Culture confirmed recurrent UTI as defined by EAU guidelines (3 per year or 2 within 6 months)
Rejection
Rejection within 12 months of surgery. If rejection has occurred, diagnostic category according to Banff Classification of Renal Allograft Pathology.

Full Information

First Posted
February 7, 2023
Last Updated
May 8, 2023
Sponsor
Rigshospitalet, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT05730257
Brief Title
Study Investigating Whether Robot-assisted Surgery Can Reduce Surgical Complications Following Kidney Transplantation
Acronym
ORAKTx
Official Title
Open-label Randomized Clinical Trial Investigating Whether Robot-Assisted Kidney Transplantation Can Reduce Surgical Complications Compared to Open Kidney Transplantation; The ORAKTx Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 8, 2023 (Actual)
Primary Completion Date
October 2025 (Anticipated)
Study Completion Date
October 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to explore whether robot-assisted surgery can reduce 30-day surgical complications compared to open surgery in kidney transplantation. Participants are adult recipients of kidney transplantation. Upon entry into the trial participants will be randomly assigned eiher open kidney transplantation or robot-assisted kidney transplantation. The participants in both groups will be treated in accordance with up-to-date guidelines and care. Our hypothesis is that robot-assisted surgery can reduce vascular complications by 15% and/or major surgical complicatons by 20% within 30 days of kidney transplantation compared to open surgery.
Detailed Description
Kidney transplantation is the ultimate surgical treatment for end stage renal disease, and while medical transplantation therapy has developed tremendously and now allows for transplantation and long-term survival, even in seemingly incompatible donors and recipients, kidney graft survival still, to a large extent, depends on a smooth and complication-free surgical procedure. In the past decade surgical techniques have been expanded by the introduction of surgical robots to improve minimally invasive surgery and optimize post-surgical care. Previous studies suggest that robot-assisted surgery has the potential to reduce complications such as surgical site infection and blood-loss, facilitate fast-track or even ambulatory surgery for complicated procedures and recent studies suggest this may be the case for kidney transplantation too. The aim of this trial is therefore to explore if robot-assisted surgery can reduce surgical complications following kidney transplantation compared to open surgery (standard of care) and investigate the patient trajectory following the two procedures in terms of late complications, graft function and mortality. The study design is a superiority, open-label randomized clinical trial to be conducted at Rigshospitalet, the largest transplantation centre in Denmark. The primary outcomes consist of 1) reduction in vascular complications (graft arterial stenosis, bleeding requiring reoperation, symptomatic haematomas, renal vascular thrombosis). The rate of vascular complications is currently 17.3%. With a power set at 80% and a significance level set at 5% we hypothesize that Robot-Assisted Kidney Transplantation (RAKT) can reduce vascular complications by 15% within 30 days after transplantation compared to Open Kidney Transplantation (OKT). 2) Reduction in surgical complications Clavien-Dindo > grade 2. The rate of Clavien-Dindo >2 is currently 22.8%. With a power set at 80% and a significance level set at 5%, we hypothesize that RAKT can reduce Clavien-Dindo >2 by 20% within 30 days after transplantation compared to OKT. The study will randomize 106 participants with an anticipated drop-out of 10% (n=96). Immediate follow-up will be 30-days after kidney transplantation to observe occurrence of primary endpoints assessed by chart review including both in- and out-patient information. Follow-up through chart review will persist for 2 years in order to monitor long-term complications and assess secondary outcomes. Participants will be randomized with a 1:1 allocation ratio using the randomization module in REDCap with differing block sizes. Dropouts will be replaced by the same randomization number to ensure equal distribution. The study is analysed as intention-to-treat. The primary endpoints are expected to be evaluated as percent of patients with complications compared between the two groups. Secondary outcomes will be represented descriptively and analysed according to the datatype. An interim analysis will be performed when 50% of the patients are enrolled in the study. Statistical analysis will be undertaken using R version 3.2 or later if available. While robot-assisted kidney transplantation is still in its experimental phase, robot-assisted surgery is not and many urological procedures use robotic assistance with excellent results. With no randomized clinical trials to date comparing RAKT to OKT, this study aims to contribute with valuable evidence on the possible benefits of RAKT for both surgical outcomes and the post-operative and long-term patient trajectory.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease, Kidney Transplant; Complications
Keywords
Kidney Transplantation, Robotic Surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
106 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Robot-assisted Kidney Transplantation (RAKT)
Arm Type
Experimental
Arm Description
Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels. Participants will be managed according to the standard protocol for renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality. The anaestethic protocol will be tailored to suit robot-assisted surgery
Arm Title
Open Kidney Transplantation (OKT)
Arm Type
Active Comparator
Arm Description
Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels. Participants will be managed according to the standard protocol for anaesthesia and renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality.
Intervention Type
Procedure
Intervention Name(s)
Robot-Assisted Kidney Transplantation
Intervention Description
Robot-Assisted Kidney Transplantation takes place with the patient under general anaesthesia. Several ports are placed in the lower abdomen, for the entry of the camera, surgical instruments and manuel access. The DaVinci robot is placed between the patient's legs and docked to the ports. The iliac vascular bed is prepared and a peritoneal cavity created laterally. The kidney is introduced through the handport, regional hypothermia obtained via iceslush in the cavity and the vessel lumens flushed with heparin. The vessels are blocked during suturing with the kidney graft vessels anastomosed end-to-side to the external iliac vessels. The kidney graft is placed in the retroperitoneal cavity and a ureterovesical anastomosis performed ad modem Woodruff over double J stent. The ureter is placed extra peritoneally, fascia closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
Intervention Type
Procedure
Intervention Name(s)
Open Kidney Transplantation
Intervention Description
Open Kidney Transplantation takes place with the patient under general anaesthesia. A jockey-stick (Gibson) incision is made in the left or right iliac fossa and the peritoneum is displaced. With the kidney under hypothermia, the iliac vascular bed is prepared, the vessel lumens flushed with heparin and a vascular clamp instrument is used to block the vessels during suturing. The kidney graft vessels are anastomosed end-to-side to the external iliac vessels and the ureterovesical anastomosis performed ad modem Woodruff over a double J stent. The kidney graft is placed in the cavity and the fascia is closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
Primary Outcome Measure Information:
Title
Vascular complications
Description
Composite outcome consisting of a) bleeding requiring reoperation, b) renal/graft vascular thrombosis, c) symptomatic hematomas d) renal/graft arterial stenosis
Time Frame
30 days after surgery
Title
Surgical complications Clavien-Dindo >grade 2
Description
All postoperative complications will be recorded and graded according to the Clavien-Dindo classification with major complications defined as >grade 2.
Time Frame
30 days after surgery
Secondary Outcome Measure Information:
Title
Length of Stay (LOS)
Description
Duration (days) of primary hospitalization. From the date of admission until the date of discharge from hospital
Time Frame
12 months
Title
Days Alive and Out of Hospital (DAOH)
Description
Number of days alive and out of hospital within 30 days from surgery
Time Frame
30 days after surgery
Title
Days Alive and Out of Hospital (DAOH)
Description
Number of days alive and out of hospital within 90 days from surgery
Time Frame
90 days after surgery
Title
Quality of Life (QOL): SF-36
Description
Patient reported health related QOL using the Short Form 36-item Health Survey
Time Frame
30 days after surgery
Title
Quality of Life (QOL): SF-36
Description
Patient reported health related QOL using the Short Form 36-item Health Survey
Time Frame
90 days after surgery
Title
Use of analgesics
Description
Average administered dose of any opiod agent (MME/day) post surgery, during in-hospital stay
Time Frame
12 months
Title
Transfusion rate
Description
Total amount of red blood cells administered (units)
Time Frame
30 days after surgery
Title
Kidney Function
Description
30-day creatinine and estimated Glomerular Filtration Rate (eGFR). Creatinine: μmol/L. eGFR calculated according to the CKD-EPI equation
Time Frame
30 days after surgery
Title
Kidney Function
Description
90-day creatinine and estimated Glomerular Filtration Rate (eGFR). Creatinine: μmol/L. eGFR calculated according to the CKD-EPI equation
Time Frame
90 days after surgery
Title
Kidney Function
Description
1-year creatinine and estimated Glomerular Filtration Rate (eGFR). Creatinine: μmol/L. eGFR calculated according to the CKD-EPI equation
Time Frame
12 months after surgery
Title
Kidney Function
Description
2-year creatinine and estimated Glomerular Filtration Rate (eGFR). Creatinine: μmol/L. eGFR calculated according to the CKD-EPI equation
Time Frame
24 months after surgery
Title
Delayed Graft Function (DGF)
Description
Need for dialysis in the first post-operative week beyond day 0, due to lack of increase in kidney function and where the cause is not urological/surgical complications or hyperkalaemia alone
Time Frame
7 days after surgery
Title
Graft loss
Description
Start of permanent dialysis and/or allograft nephrectomy
Time Frame
30 days after surgery
Title
Graft loss
Description
Start of permanent dialysis and/or allograft nephrectomy
Time Frame
90 days after surgery
Title
Graft loss
Description
Start of permanent dialysis and/or allograft nephrectomy
Time Frame
24 months after surgery
Title
30-day Mortality
Description
30-day all cause mortality rate and cause of death
Time Frame
30 days after surgery
Title
90-day Mortality
Description
90-day mortality rate and cause of death
Time Frame
90 days after surgery
Title
1-year Mortality
Description
1-year mortality rate and cause of death
Time Frame
12 months after surgery
Title
2-year Mortality
Description
2-year mortality rate and cause of death
Time Frame
24 months after surgery
Title
Specific urological surgical complications
Description
Ureteral strictures, urinary leak, hydronephrosis, symptomatic lymphocele; including, when needed, designated intervention (nephrostomy, JJ stent, reimplantation, drain, surgery)
Time Frame
30 days after surgery
Title
Late & specific urological surgical complications
Description
Ureteral strictures, urinary leak, hydronephrosis, symptomatic lymphocele; including, when needed, designated intervention (nephrostomy, JJ stent, reimplantation, drain, surgery)
Time Frame
90 days after surgery
Title
Late & specific urological surgical complications
Description
Ureteral strictures, urinary leak, hydronephrosis, symptomatic lymphocele; including, when needed, designated intervention (nephrostomy, JJ stent, reimplantation, drain, surgery)
Time Frame
24 months after surgery
Title
Time to return to work
Description
Whether participants have resumed a paying job 90 days after surgery. If yes: time in months from operation until any degree of work is resumed
Time Frame
90 days after surgery
Title
Recurrent urinary tract infection (UTI)
Description
Culture confirmed recurrent UTI as defined by EAU guidelines (3 per year or 2 within 6 months)
Time Frame
90 days after surgery
Title
Recurrent urinary tract infection (UTI)
Description
Culture confirmed recurrent UTI as defined by EAU guidelines (3 per year or 2 within 6 months)
Time Frame
24 months after surgery
Title
Rejection
Description
Rejection within 12 months of surgery. If rejection has occurred, diagnostic category according to Banff Classification of Renal Allograft Pathology.
Time Frame
12 months after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult recipients for renal transplantation Both patients in dialysis as well as pre-emptive For recipients of kidney grafts from deceased donors, inclusion depends on the availabilty of the robotic platform and dedicated surgical team Exclusion Criteria: High degree of calcification of the iliac vessels on the level of external iliac artery defined as occurrence of longitudinal plaques on non-contrast CT-scan in recipient prior to transplantation Highly complex vascular anatomy in the donor kidney requiring multiple anastomoses as evaluated by surgeon Previous kidney transplantation with later allograft nephrectomy as evaluated by the surgeon preoperatively Patients whose abdominal anatomy may prohibit access to and placement of graft in the iliac fossa as evaluated by the surgeon preoperatively (i.e. previous laparotomy, rectal surgery, herniotomy, current multiple kidney cysts) Simultaneous multiple organ transplant Severe comorbidities contraindicating robot-assisted surgery Patients who are unable to understand relevant medical information and the implications of treatment alternatives and to make an independent, voluntary decision
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Milla Ortved, MD
Phone
+4535456152
Email
milla.ortved@regionh.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Andreas Roeder, MD, PhD
Phone
+4535457195
Email
andreas.roeder@regionh.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas Roeder, MD, PhD
Organizational Affiliation
Rigshospitalet, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Urological Research Unit, Rigshospitalet
City
Copenhagen
State/Province
N
ZIP/Postal Code
2200
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Milla Ortved
Facility Name
Department of Nephrology, Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Søren Schwartz Sørensen

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
All study data including study protocol, statistical analysis plan, informed consent form, and clinical study report can be shared when a proper agreement is formed according to the European Union (EU) General Data Protection Regulation (GDPR) protection statement.

Learn more about this trial

Study Investigating Whether Robot-assisted Surgery Can Reduce Surgical Complications Following Kidney Transplantation

We'll reach out to this number within 24 hrs